$KRYS News
Last published 1w ago
- 1w agoKRYSKrystal Biotech 3Q 2026 Conference Call - KRYSTAL BIOTECH INCEarnings Call TranscriptsGood morning, and thank you for standing by, and welcome to Crystal Biotech's third quarter 2026 earnings conference call. At this time, all participants are on a listen-only mode. After the speakers' presentations, ther
- 1w agoKRYSKrystal Biotech, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 1w agoKRYSKrystal Biotech Announces Third Quarter 2026 Financial and Operating ResultsGlobeNewswire$127.3 million in 3Q VYJUVEK global revenue and $1.1 billion since launch VYJUVEK pricing negotiations in Germany and Italy completed KB113 clinical data demonstrate regression in more than 80% of assessed basal cell
- 2w agoKRYSKrystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026GlobeNewswirePITTSBURGH, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) announced today that it will report its third quarter 2026 financial results on Monday, November 2, 2026, prior
- 3w agoKRYSKrystal Biotech Announces Positive Clinical Data for New Dermatology Program KB113 Demonstrating Broad Basal Cell Carcinoma Regression in Patients with Gorlin SyndromeGlobeNewswireOver 80% of assessed basal cell carcinoma lesions regressed across three Gorlin syndrome patients treated with KB113 Substantial regression was observed in lesions not directly injected with KB113, consistent with
- 2mo agoKRYSKrystal Biotech to Present at 2026 Cantor Global Healthcare ConferenceGlobeNewswirePITTSBURGH, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today announced that the Company will participate in the 2026 Cantor Global Healthcare Conference on September
- 3mo agoCNXUVCELAXGNKRYS+1Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill ItGlobeNewswireRENO, Nev., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - For thirty years the answer to lost facial and body volume has been to put something back in. Fillers occupy space, implants occupy
- 3mo agoKRYSKrystal Biotech 2Q 2026 Conference Call - KRYSTAL BIOTECH INCEarnings Call TranscriptsThank you for standing by, and welcome to the Crystal Biotech 2Q 2026 conference call. At this time, all participants have been placed on a listen-only mode. After the speakers' presentations, there will be a question-an
- 3mo agoKRYSKrystal Biotech Announces Second Quarter 2026 Financial and Operating ResultsGlobeNewswire$119.2 million in 2Q VYJUVEK global revenue and $965.9 million since launch Multiple clinical data readouts in 2H 2026 On track for VYJUVEK launches in Spain and Italy later this year Strong balance sheet, ending the
- 3mo agoKRYSKrystal Biotech to Report Second Quarter 2026 Financial Results on August 3, 2026GlobeNewswirePITTSBURGH, July 23, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) announced today that it will report its second quarter 2026 financial results on Monday, August 3, 2026, prior
- 5mo agoCRBPKRYSCorbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference CallGlobeNewswireNORWOOD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced that
- 5mo agoKRYSKrystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis BullosaGlobeNewswireVYJUVEK approved for the treatment of DEB from birth with flexible administration options similar to those already granted in the United States, European Union, and Japan VYJUVEK is the first genetic medicine approved
- 6mo agoKRYSKrystal Biotech to Present at BofA Securities 2026 Health Care ConferenceGlobeNewswirePITTSBURGH, May 07, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today announced that the Company will participate in the BofA Securities 2026 Health Care Conference on May 13, 2026, in
- 6mo agoKRYSKrystal Biotech Announces First Quarter 2026 Financial and Operating ResultsGlobeNewswire$116.4 million in 1Q VYJUVEK global revenue and $846.7 million since launch Enrollment complete in KB803 (corneal abrasions in DEB patients) registrational study On track for KB803 and KB801 (NK) registrational data
- 6mo agoKRYSKrystal Biotech to Present at Upcoming Scientific ConferencesGlobeNewswirePITTSBURGH, April 30, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) announced today that the Company will be presenting on multiple programs at upcoming scientific conferences being held
- 6mo agoKRYSKrystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026GlobeNewswirePITTSBURGH, April 21, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) announced today that it will report its first quarter 2026 financial results on Monday, May 4, 2026, prior to the open
- 7mo agoKRYSPVLAPalvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient ServicesGlobeNewswireMs. McDonough previously served as Senior Vice President of Patient Access, Analytics, and Operations at Krystal Biotech (NASDAQ:KRYS), where she helped lead the U.S. launch of VYJUVEK®, supporting its growth from
- 8mo agoKRYSKrystal Biotech to Present at TD Cowen 46th Annual Health Care ConferenceGlobeNewswirePITTSBURGH, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today announced that the Company will participate in the TD Cowen 46th Annual Health Care Conference on March 3, 2026,
- 8mo agoKRYSKrystal Biotech Announces Fourth Quarter and Full Year 2025 Financial and Operating ResultsGlobeNewswire$107.1 million in 4Q VYJUVEK revenue and $730.3 million since U.S. launch FDA granted RMAT to KB707 for the treatment of advanced NSCLC and Fast Track Designation to KB111 for the treatment of HHD Strong balance sheet,
- 9mo agoKRYSKrystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026GlobeNewswirePITTSBURGH, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) announced today that it will report its fourth quarter and full year 2025 financial results on Tuesday, February 17,
- 9mo agoKRYSKrystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung CancerGlobeNewswirePITTSBURGH, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) announced today that the United States Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy
- 10mo agoKRYSKrystal Biotech Provides Business Update at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswirePreliminary 4Q 2025 VYJUVEK net revenue of $106 million to $107 million Robust clinical pipeline with multibillion dollar opportunities and strong balance sheet for sustained growth PITTSBURGH, Jan. 11, 2026 (GLOBE
- 10mo agoKRYSKrystal Biotech KB407 Clinical Update - KRYSTAL BIOTECH INCEarnings Call TranscriptsThank you for standing by and welcome to Crystal Biotech's clinical update call for Cystic Fibrosis Programme KB407. At this time, all participants are in a listen-only mode. After the speaker's presentations, there will
- 10mo agoKRYSKrystal Biotech Announces Positive Interim Clinical Update from KB407 Phase 1 CORAL-1 Study with Confirmation of Wild-Type CFTR Delivery to the Lungs of Patients with Cystic FibrosisGlobeNewswireConfirmed wild-type CFTR delivery and expression in conducting airway cells of patients with class I mutations KB407 transduction confirmed in all six patients with successful bronchoscopies irrespective of
- 10mo agoKRYSKrystal Biotech to Announce Interim Clinical Update from Highest Dose Cohort of Phase 1 CORAL-1 Study Evaluating KB407 in Patients with Cystic FibrosisGlobeNewswirePITTSBURGH, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today announced that it will host an investor conference call and webcast tomorrow, Thursday, January 8, 2026, at 4:30
- 10mo agoKRYSKrystal Biotech to Present at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswirePITTSBURGH, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today announced that the Company will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 12,
- 11mo agoKRYSKrystal Biotech to Present at 8th Annual Evercore Healthcare ConferenceGlobeNewswirePITTSBURGH, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today announced that the Company will participate in the 8th Annual Evercore Healthcare Conference on December 3, 2025,
- 1y agoKRYSKrystal Biotech Announces Third Quarter 2025 Financial and Operating ResultsGlobeNewswire$97.8 million in 3Q VYJUVEK revenue and $623.2 million since U.S. launch VYJUVEK launched in Germany in 3Q; launched in France and Japan in 4Q Updated U.S. VYJUVEK label expands eligible patient population and
- 1y agoKRYSKrystal Biotech to Report Third Quarter 2025 Financial Results on November 3, 2025GlobeNewswirePITTSBURGH, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) announced today that it will report its third quarter 2025 financial results on Monday, November 3, 2025, prior to the
- 1y agoKRYSKrystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic KeratitisGlobeNewswirePITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) announced today that the United States Food and Drug Administration (FDA) granted platform technology designation to the
- 1y agoKRYSKrystal Biotech Announces FDA Approval of Updated VYJUVEK® LabelGlobeNewswireRevised label allows treatment of DEB patients from birth VYJUVEK can now be applied by patients and caregivers PITTSBURGH, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company")
- 1y agoKRYSKrystal Biotech to Present at Cantor Global Healthcare Conference 2025GlobeNewswirePITTSBURGH, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today announced that the Company will participate in the Cantor Global Healthcare Conference 2025 on September 4, 2025,
- 1y agoKRYSKrystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung CancerGlobeNewswirePITTSBURGH, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS), a commercial-stage biotechnology company, today announced an update on development plans for KB707, the Company's
- 1y agoKRYSKrystal Biotech, Inc. (KRYS) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoKRYSKrystal Biotech Announces Second Quarter 2025 Financial and Operating ResultsGlobeNewswire$96.0 million in 2Q VYJUVEK revenue and $525.4 million since launch in 3Q 2023 VYJUVEK approved in Japan for the treatment of DEB patients from birth Strong balance sheet, ending the quarter with $820.8 million
- 1y agoKRYSKrystal Biotech to Report Second Quarter 2025 Financial Results on August 4, 2025GlobeNewswirePITTSBURGH, July 29, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS), a commercial-stage biotechnology company, today announced that it will report its second quarter 2025 financial results
- 1y agoKRYSKrystal Biotech Announces Approval of VYJUVEK® by Japan's Ministry of Health, Labour and Welfare for the Treatment of Dystrophic Epidermolysis BullosaGlobeNewswireVYJUVEK approved for the treatment of DEB from birth with flexible administration options including home dosing and the option for administration by the patient or their family VYJUVEK is the first and only genetic
- 1y agoKRYSJeune Announces Positive Results and Significant Aesthetic Improvements from Phase 1 Study of KB304 for Moderate to Severe Wrinkles of the DécolletéGlobeNewswireKB304 designed to deliver collagen and elastin to restore skin naturally Conference call to discuss results scheduled for Thursday, July 24, 2025 at 4:30pm ET PITTSBURGH, July 24, 2025 (GLOBE
- 1y agoKRYSKrystal Biotech Announces First Patient Dosed in Phase 3 Clinical Trial of KB803 for the Treatment and Prevention of Corneal Abrasions in Patients with Dystrophic Epidermolysis BullosaGlobeNewswireIntra-patient, double-blind, multicenter, placebo-controlled study with crossover design Repeat administration under compassionate use was previously shown to be well tolerated and associated with full corneal healing
- 1y agoKRYSKrystal Biotech to Present at Goldman Sachs 46th Annual Global Healthcare ConferenceGlobeNewswirePITTSBURGH, June 03, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today announced that the Company will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on June
- 1y agoKRYSKrystal Biotech to Present at BofA Securities 2025 Health Care ConferenceGlobeNewswirePITTSBURGH, May 07, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today announced that the Company will participate in the BofA Securities 2025 Health Care Conference on May 14, 2025, in
- 1y agoKRYSKrystal Biotech Announces First Quarter 2025 Financial and Operating ResultsGlobeNewswireVYJUVEK approved in Europe for the treatment of DEB patients from birth $88.2 million in 1Q VYJUVEK revenue and $429.4 million since launch in Q3 2023 Second ophthalmic program in clinic - KB801 for the treatment of
- 1y agoKRYSKrystal Biotech Announces European Commission Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis BullosaGlobeNewswireVYJUVEK approved for the treatment of DEB from birth in Europe Approval allows for dosing at home or in a healthcare setting, as well as patient or caregiver administration if deemed appropriate by a healthcare
- 1y agoKRYSKrystal Biotech to Present at Upcoming Scientific ConferencesGlobeNewswirePITTSBURGH, April 24, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) announced today that the Company will be presenting on multiple programs in the lung, eye, and skin at upcoming
- 1y agoKRYSKrystal Biotech to Report First Quarter 2025 Financial Results on May 6, 2025GlobeNewswirePITTSBURGH, April 17, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS), a commercial-stage biotechnology company, today announced that it will report its first quarter 2025 financial results
- 1y agoKRYSJeune Aesthetics Appoints Marc Forth as Chief Executive OfficerGlobeNewswirePITTSBURGH, April 07, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. ("Jeune"), a wholly owned subsidiary of Krystal Biotech, Inc. ("Krystal") (NASDAQ:KRYS) leveraging Krystal's clinically validated gene-delivery
- 1y agoKRYSKrystal Biotech Receives Positive CHMP Opinion for VYJUVEK® for the Treatment of Dystrophic Epidermolysis BullosaGlobeNewswirePITTSBURGH, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS), a commercial-stage biotechnology company, today welcomed the European Medicines Agency's (EMA's) announcement that
- 1y agoKRYSKrystal Biotech to Present at TD Cowen 45th Annual Health Care ConferenceGlobeNewswirePITTSBURGH, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the TD Cowen 45th Annual
- 1y agoKRYSKrystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating ResultsGlobeNewswireFourth quarter revenues increased 116% to $91.1 million versus fourth quarter of 2023 Full year revenues increased 473% to $290.5 million versus 2023 CFF TDN granted full sanctioning of KB407 Phase 1 protocol Strong
- 1y agoKRYSKrystal Biotech to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025GlobeNewswirePITTSBURGH, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS), a commercial-stage biotechnology company, today announced that it will report its fourth quarter and full year 2024